The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Yasmeen Rahimi - Piper Sandler & Co. - Analyst
: Good morning, team, and thank you so much for all the great updates. And to the extent you can comment on in for the MOMENTUM data, like I
know it's set for this quarter, enrollment finished in September. Any chance this is going to potentially come around this month or next month. So
to the extent you could provide a little bit color on when in this quarter, we should be expecting it.
I know in the past. Second question is in the past you guys spoken about also at the top line to provide some modeling analysis to be able to look
at the curve of weight loss. I just wanted to make sure that's still occurring as we head into the top-line data.
And then maybe the third question is just some cadence on given that impact has a weight loss and a really desirable product profile and what is
the enthusiasm among sites and patients as they have eligibility to be part of the study. So appreciate if you could tackle those three for me, and
I'll jump back into the queue.
Question: Yasmeen Rahimi - Piper Sandler & Co. - Analyst
: Okay. Thank you so much. I'll jump back in the queue.
Question: Roger Song - Jefferies. - Analyst
: Great, congrats for the progress, and thanks for the update. Few questions from us. So the first one is regarding the you know, assuming the
MOMENTUM Phase 2 data meeting your expectation and how, what is your current thinking around the Phase 3 design, particularly around the
dosing and the titration given you know, we see it a bit higher discontinued due to AI, in Phase 2, which is similar to other Phase 2.
But in Phase 3, you probably want a lower data rate for Phase 2. Just remind us of what is your current thinking at, for the design portion? And
second question is related to that partnership, so I think on the call you mentioned you will start a Phase 3 in second half next year with a partner.
Maybe just, can you give us some color around the panel discussion at this point, particularly with the MOMENTUM for the 48-week data hall and
when will trigger additional discussion to make this material? Thank you.
Question: Roger Song - Jefferies. - Analyst
: Excellent, thank you, that's it from me.
Question: Jonathan Wolleben - JMP Securities LLC - Analyst
: Hi, thanks for taking the questions. I guess two for me. One, a follow-up from an earlier question. How do you think about an acceptable tolerability
profile than in the upcoming MOMENTUM readout, given in the tweaks, Scott, you just discussed you can make going into Phase 3, and then can
you also discuss the differentiation from peptide to other GLP-1/glucagon dual agonist and [Bi] compounds, either structurally or even from the
data we've seen. And we've gotten pretty good benefits from all three at this point, I think there would be helpful to hear. Thanks.
Question: Jonathan Wolleben - JMP Securities LLC - Analyst
: Thanks for the color, Scott.
|
